- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
ILSI-Biomed Israel 2007
Needham Biotechnology & Medical Technology Conference 2007
RedChip Small-Cap Investor Conference
BioSante Pharmaceuticals (AMEX:BPA) today announced that Stephen M. Simes, its president and chief executive officer, will present a corporate overview and update at upcoming conferences. The conferences are:
* The RedChip Small-Cap Investor Conference today, May 30, 2007 at 10:30 a.m. local time at the Ritz Carlton in San Francisco.
* The BioMed 2007 Conference on June 7th at approximately 10:00 a.m. local time at the David Intercontinental Hotel in Tel-Aviv, Israel.
* The Needham Biotechnology and Medical Technology Conference on June 13th at 8:00 a.m. local time at the New York Palace Hotel.
A live audio webcast of BioSante's presentation at the RedChip and Needham conferences can be accessed on the internet by visiting http://www.biosantepharma.com . An archive of these presentations will be available at the same address.
These conferences each feature companies presenting to a diverse group of investors and analysts interested in the biotechnology and pharmaceuticals sectors as well as industry representatives.
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bio-identical estradiol and testosterone. BioSante's lead products include Elestrin™ (estradiol gel), developed through U.S. Food and Drug Administration (FDA) approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and LibiGel® (transdermal testosterone gel) in Phase III development for the treatment of female sexual dysfunction (FSD). The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration.
For more information, please click here
BioSante Pharmaceuticals, Inc.
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Cooling graphene-based film close to pilot-scale production April 30th, 2016
Personal cooling units on the horizon April 29th, 2016
Exploring phosphorene, a promising new material April 29th, 2016
Researchers create a first frequency comb of time-bin entangled qubits: Discovery is a significant step toward multi-channel quantum communication and higher capacity quantum computers April 28th, 2016
Introducing the RE標ORK Bio-inspired Robotics Summit in Berlin April 27th, 2016